RetinAI announces a collaboration with Isarna Therapeutics

Bern, Switzerland, 1st December 2021 - RetinAI Medical AG announced a collaboration with Isarna Therapeutics under which RetinAI’s IT solutions and artificial intelligence tools, including RetinAI Discovery®, shall be employed to support The BETTER Study, an international clinical trial evaluating the efficacy of ISTH0036 for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME).

nAMD affects an estimated 20 to 25 million people worldwide and is a leading cause of severe vision loss, with all the accompanying challenges that brings. DME is also a leading cause of blindness, and the main cause of blindness in people with diabetes, affecting an estimated 21 million people across the world. These numbers continue to rise as the global population ages.

Discovery® will be used to support this multicenter clinical study involving patients with nAMD and DME. The main objective of the study is to investigate the efficacy of ISTHOO36 administered with intravitreal injections.

For this study, RetinAI will provide its CE-marked web-based software platform, RetinAI Discovery®, a data management platform to efficiently process data at scale across imaging platforms and devices. Discovery® is used today by healthcare and clinical research professionals to navigate imaging data, compute imaging biomarkers and track changes over time for some of the most common forms of eye diseases.

RetinAI’s tools support diagnostic analyses and clinical workflows for patient monitoring & monitoring of treatment outcomes based on organization of insights and knowledge.

“We are generating valuable patient data at pace and need swift and comprehensive insights to better manage and treat patients and diseases. That is what RetinAI can do to the benefit of patients, physicians and Isarna” commented Prof. Marion R. Munk, MD, PhD, FEBO, the CMO of Isarna. “We are working with RetinAI and Discovery® provides an opportunity to efficiently collect, share and interpret images with advanced AI tools in a timely manner as the trial proceeds. Therefore, we are very pleased to enter into this collaboration” added Dr. René Rückert, COO of Isarna.

Dr. Carlos Ciller, CEO of RetinAI, commented “RetinAI is excited to expand and further develop our relationship with Isarna Therapeutics who is focusing on ophthalmology with deep competence, dedication and focus on antisense therapies targeting the emerging therapeutic field of TGF-β signaling. We clearly see the value that RetinAI can bring to Isarna. Our Discovery® platform and AI tools are enablers to increase efficiency in research and clinical studies and we expect they can also improve medications and treatments for patients by providing enhanced data insights.

About RetinAI

RetinAI Medical AG (RetinAI), founded in early 2017, is a Swiss company in Bern developing software solutions to accelerate clinics, research and pharmaceutical workflows using advanced machine learning and computer vision. The company builds tools to collect, organize and analyze health data from the eyes, empowering healthcare professionals and patients with unique medical data analyses supported by Artificial Intelligence. RetinAI's international team combines clinical, technical, and scientific knowledge to foster the transition from reactive to preventive medicine for severe diseases affecting the eye.

About RetinAI Discovery®: Retinai Discovery® is a standalone medical image and data platform that allows trained healthcare professionals (physicians, ophthalmologists, opticians, clinicians and researchers) in a healthcare provider to store, search, share, display, navigate, process and grade medical images of the eye and e-CRF (electronic Case Report Form).

About Isarna
Isarna Therapeutics is a clinical stage company based in Munich, Germany. Isarna was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - TGF-β signaling. Precise modulation of TGF-β pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Our lead compound, ISTH0036, is about to enter Phase 2 clinical development in Ophthalmology in the indications neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME). In addition, Isarna has established a portfolio of antisense compounds addressing three important isoforms of TGF-β to treat fibrotic liver disease, such as NASH, and various forms of cancer.

Press contact

RetinAI Medical AG

Carlos Ciller, PhD

CEO RetinAI Medical AG

Isarna Therapeutics GmbH

René Rűckert, M.D., M.B.A.

Chief Operating Officer Isarna Therapeutics GmbH

Rene Ruckert